Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
It is typically temporary and often occurs as your body adjusts to the medication, usually in the first few weeks
A smaller number of patients also report fatigue or GI issues that can lead to discontinuation
This investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously is being studied for obesity and type 2 diabetes management, with early-phase data showing promising results
Studies using magnetic resonance imaging (MRI) and proton density fat fraction (MRI-PDFF) measurements have shown significant reductions in hepatic steatosis with semaglutide and liraglutide treatment
US$ 26.46
US$ 23.17
US$ 28.02
